Unlearn.AI

We’re excited to attend AD/PD - Advances in Science & Therapy 2025 in Vienna in a couple of weeks! Don’t miss our presentation, “Applications of Digital Twins of Alzheimer’s Disease Participants for Designing Efficient Trials and Improving Confidence in Decision-Making,” in collaboration with AbbVie, and our poster, “Machine Learning Model Enables Accelerated Enrollment Timelines in Parkinson’s Disease Clinical Trials.” Connect with our team to learn how our AI-powered solutions are revolutionizing clinical trials by optimizing trial design, enhancing power, simulating outcomes, and more—delivering faster results, reducing millions in costs, and accelerating life-saving therapies to patients. ??

The Alzheimer's & Parkinson's drug development summit kicks off in Boston today. Unlearn.AI will be presenting encouraging results from our collaboration on the use of ?????????????? ?????????? to predict disease progression in a Phase 2a trial for mild-to-moderate Alzheimer's. Using digital twins, we could validate preliminary results on tau pathology biomarkers. If you are at the summit, check out the presentation by Yujia(Susanna) Qiao of Unlearn.AI tomorrow (Wednesday) at 2 pm.

Excited for AD/PD Boston! Our presentation, “Use of digital twins in a Phase 2a trial to predict disease progression of participants with mild-to-moderate Alzheimer’s supports early signals of efficacy,” created in collaboration with remynd, highlights how digital twins validated preliminary results on tau pathology biomarkers. This innovative approach provides valuable additional evidence supporting the advancement of the clinical program. ?? Session name: Enhancing the Landscape of Anti-Amyloids & Evaluating Combination Approaches ? Date/time: March 19 at 2 PM ET ??? Presenter: Yujia(Susanna) Qiao

?? Our Senior Director of Clinical Affairs, Luis Olmos, PhD, MBA, will be presenting at the Digital Innovations in Clinical Trials conference on March 20-21 in Berlin. His presentation, “Enhancing Clinical Trials with Digital Twins: Improving Design, Decision-Making, and Enrollment Speed” will offer expert insights into how #digitaltwins are being used to revolutionize #clinicaltrials. ——— TBM Group

? ???????????????? ?????????????? ????????????????????????! We are delighted to welcome Luis Olmos, PhD, MBA Senior Director of Clinical Affairs at Unlearn.AI, as a speaker at the ?????????????? ?????????????????????? ???? ???????????????? ???????????? ????????????????????! ?? ????????: ???????? & ???????? ?????????? ???????? ??????????????????: ????????????, ?????????????? ?? ??????????: "?????????????????? ???????????????? ???????????? ???????? ?????????????? ??????????: ?????????????????? ????????????, ????????????????-????????????, ?????? ???????????????????? ??????????" Luis will provide expert insights into how Digital Twins are revolutionizing clinical trials, optimizing trial design, accelerating decision-making, and improving patient enrollment. Join us in Berlin to explore cutting-edge advancements in clinical research! ?? https://tbmgroup.eu/blog/ https://lnkd.in/dm7kXTPk

Join Unlearn and Women In Data?? for an engaging networking event on "Revolutionizing Healthcare with AI: Perspectives, Innovations, and Challenges." Connect with industry leaders, data scientists, and healthcare professionals as we explore groundbreaking AI advancements, real-world applications, and the challenges shaping the future of healthcare. Whether you're a seasoned expert or just starting, this is a great opportunity to learn, collaborate, and expand your network in the AI and healthcare space. ?? ?? RSVP here: https://bit.ly/41Lj8I5

?? Our Founder and VP of Technology, Jonathan Walsh, will be presenting at The National Academies of Sciences, Engineering, and Medicine Gilbert W. Beebe Symposium on #AI and #ML Applications on March 14. His presentation, “Digital Twins for Disease Modeling and Drug Development: Applications for Smarter, Faster Clinical Trials,” will focus on leveraging #machinelearning models to create #digitaltwins that accurately predict a patient’s future health and explore their use in optimizing trial design, enhancing trial power, simulating outcomes, and modeling treatment responses in individuals or subgroups.

It was great to attend the Clinical Trials Innovation Programme and see the growing focus on the transformative role of #AI in #clinicaltrials. The discussions highlighted how AI is set to become a key part of clinical trial workflows, improving efficiency, outcomes, and patient-centricity. This aligns closely with our mission to revolutionize #clinicaldevelopment with AI—accelerating innovation and bringing therapies to patients faster. ?? ——— World BI; Clinical Trials Conclave (CTC) ?? Pictured: Jacqueline Blem, Cardiff Clinical

Heading to the 13th Annual Alzheimer’s and Parkinson’s Drug Development Summit in Boston? Don’t miss the opportunity to meet with our team and learn how AI-generated #digitaltwins are transforming #clinicaltrials —streamlining timelines, cutting costs, and driving confident decision-making. ?? ——— Anurag Kulkarni; Yujia(Susanna) Qiao; Martin Koch

In this essay for pharmaphorum, Unlearn’s Head of Business Development, Andrew Stelzer, asks, “How can companies developing real, high-impact AI-powered solutions for #clinicaltrials stand out by shifting their focus from 'how' to 'why'?” and explains how Recursion has mastered the art of staying above the #AI hype. https://bit.ly/3FfdzJ5